May 30, 2024
Dr Xavier Jacq and Dr Olivia Rossanese have joined Evariste's Board of Directors
Evariste has recently appointed two new board members. We welcome Dr Xavier Jacq and Dr Olivia Rossanese, who will be advising Evariste's scientific strategy.
Dr Xavier Jacq currently serves as the CSO of Moa Technology. He was Co-founder of Mission Therapeutics, former VP of Biology at Almac Discovery, and former SVP at Dunad Therapeutics. With over 20 years of experience in the biotech industry, Xavier has been instrumental in driving innovative research and development in the field of therapeutic discovery.
Dr Olivia Rossanese is Director of Drug Discovery and Head of Division for Cancer Therapeutics at the Institute of Cancer Research (ICR), and was previously a member of GSK's TafinlarⓇ discovery team. Olivia has extensive experience leading and contributing to discovery and target validation programmes, as well as identification of tool molecules, lead compounds, clinical candidates.
We look forward to working with both Xavier and Olivia and tapping in to their vast expertise during this exciting time for Evariste.
Stay updated with Evariste's blogposts
Stay updated with Evariste's blogposts
Stay updated with Evariste's blogposts
Stay updated with Evariste's blogposts
Stay updated with Evariste's blogposts
Stay updated with Evariste's blogposts
.png)
